Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancerPatient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancerPhase III results in Chinese patients with metastatic naso